Global Liposome Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Liposome Injection Market Research Report 2024
Liposomes are lipid microcapsules composed of an amphiphilic lipid bilayer (monolayer) and/or a series of concentric discontinuous aqueous compartments separated by a series of multiple amphiphilic bilayers. In liposome drugs, the drug is contained in liposomes. In general, water-soluble drugs are often encapsulated in the aqueous compartment, and lipophilic drugs are encapsulated in the lipid bilayer of the liposome.
According to Mr Accuracy reports new survey, global Liposome Injection market is projected to reach US$ 916.7 million in 2029, increasing from US$ 637.3 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposome Injection market research.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses. Global Use of Medicines 2024 shows that, based on net ex-factory prices, the U.S. market will spend about $62.9 billion on medicines in 2022. Overall growth slows as the Inflation Reduction Act (IRA) spends $64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years, with ex-factory discounts and rebates in the drug pipeline , the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liposome Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
CSPC
Luye Pharma
Fudan Zhangjiang
Nanjing Cisco
Qilu Pharmaceutical
Sichuan Kelun
Modern Medicine
Eudinamis
Indiamart
Getwelloncology
Polymun
Segment by Type
Doxorubicin Hydrochloride Liposome Injection
Mitoxantrone Hydrochloride Liposome Injection
Irinotecan Hydrochloride Liposome Injection
Others
Malignant Tumor Treatment
Infection Treatment
Post-operative Pain Relief
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Liposome Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Liposome Injection market is projected to reach US$ 916.7 million in 2029, increasing from US$ 637.3 million in 2022, with the CAGR of 5.3% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Liposome Injection market research.
According to the "Global Use of Medicines 2024" released by the IQVIA Institute, the global drug expenditure in 2022 will be approximately US$1.48 trillion (excluding costs related to COVID vaccines and therapies), and it is predicted that it will grow at a rate of 3%-6% in the next few years. In terms of regional development trends, high-income countries such as Western Europe, North America, and Japan are expected to experience slower growth in the next few years due to already high per capita usage, while growth markets such as Asia, Latin America, and Eastern Europe are expected to grow strongly. In terms of drug expenditure, China's drug expenditure in 2022 will be about 166 billion US dollars. It is expected that the expenditure on medicines will only increase in the next few yearsFrom the perspective of demand, the trend of population aging, the increase of residents’ wealth and the improvement of health awareness will drive the demand for medicines; from the perspective of national strategy, in 2016 , the State Council issued the "Healthy China 2030" Planning Outline, and "Healthy China" has risen to a national strategy; from the perspective of industry policy, it has experienced the uncertainty brought about by the initial stage of medical reform, the implementation of the centralized procurement policy and the expansion of the drug reimbursement catalog The update will gradually achieve a dynamic balance of multiple goals such as promoting innovation, stabilizing supply, and reducing the burden on the masses. Global Use of Medicines 2024 shows that, based on net ex-factory prices, the U.S. market will spend about $62.9 billion on medicines in 2022. Overall growth slows as the Inflation Reduction Act (IRA) spends $64 billion to reduce prescription drug prices, and the adoption of new treatments is expected to increase over the next few years, with ex-factory discounts and rebates in the drug pipeline , the impact of patent expiration, and generic or biosimilar competition will also affect the U.S. pharmaceutical market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Liposome Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
CSPC
Luye Pharma
Fudan Zhangjiang
Nanjing Cisco
Qilu Pharmaceutical
Sichuan Kelun
Modern Medicine
Eudinamis
Indiamart
Getwelloncology
Polymun
Segment by Type
Doxorubicin Hydrochloride Liposome Injection
Mitoxantrone Hydrochloride Liposome Injection
Irinotecan Hydrochloride Liposome Injection
Others
Segment by Application
Malignant Tumor Treatment
Infection Treatment
Post-operative Pain Relief
Others
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
The Liposome Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices